OPEN ACCESS pISSN 2234-3806
eISSN 2234-3814

Table. 1.

Table. 1.

Antifungal susceptibility of the Lichtheimia ornata isolate from this study and previously reported Lichtheimia spp. and their clinical information

Antifungal agent Time (hrs) assessed MIC or MEC* (μg/mL) for:
L. ornata (this study) L. ornata, previously reported in rhinocerebral mucormycosis [4] L. ornata, previously reported [9]
Amphotericin B 24/48 2/4 2/NA 0.12/0.12
Anidulafungin 24/48 4/>8 4/32
Micafungin 24/48 >8/>8 >256/NA 32/32
Caspofungin 24/48 >8/>8 >16/NA 32/32
5-flucytosine 24/48 >64/>64 >64/NA
Posaconazole 24/48 1/1 2/NA 0.25/0.25
Voriconazole 24/48 >8/>8 >16/NA 16/16
Itraconazole 24/48 0.5/1 1/NA 0.5/1
Fluconazole 24/48 >256/>256 >64/NA
Clinical information L. ornata (this study) L. ornata, previously reported in rhinocerebral mucormycosis [4] L. ornata, previously reported [9]
Age (yr)/sex 67/F 40/F NA
Organ involvement Lungs Rhino-orbital-cerebral region NA
Underlying condition Acute lymphoblastic leukemia Aplastic anemia, after allogeneic hematopoietic stem cell transplantation NA
Diagnosis Pulmonary mucormycosis Rhinocerebral mucormycosis NA
Treatment Liposomal amphotericin B Amphotericin B NA
Outcome Cured Died NA

*Cut-off values for echinocandins (anidulafungin, micafungin and caspofungin) are interpreted as minimal effective concentration instead of minimal inhibitory concentration [7].

Abbreviations: MIC, minimal inhibitory concentration; MEC, minimal effective concentration (calculated for echinocandins); NA, not available; F, female.

Ann Lab Med 2024;44:371~374 https://doi.org/10.3343/alm.2023.0426

© Ann Lab Med